Valuation: China Shineway Pharmaceutical Group Limited

Market Cap 4.81B 724M 650M 598M 541M 1.01B 68.73B 1.03B 7.12B 2.85B 36.19B 2.72B 2.66B 114B P/E 2026 *
6.37x
P/E 2027 * 5.93x
Enterprise Value 4.81B 724M 650M 598M 541M 1.01B 68.73B 1.03B 7.12B 2.85B 36.19B 2.72B 2.66B 114B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 2.05x
Free-Float
33.69%
Yield 2026 *
-
Yield 2027 * -
1 day-21.87%
Current month-21.87%
1 month-21.87%
3 months-12.78%
6 months-12.78%
Current year-12.78%
1 month 16.79
Extreme 16.79
21.78
Current year 16.79
Extreme 16.79
22.23
1 year 16.79
Extreme 16.79
22.23
3 years 16.79
Extreme 16.79
27.85
5 years 12.12
Extreme 12.12
27.85
10 years 12.12
Extreme 12.12
27.85
Manager TitleAgeSince
Investor Relations Contact 60 -
Sales & Marketing 46 2019-11-30
Comptroller/Controller/Auditor 53 2011-01-31
Director TitleAgeSince
Chairman 70 2002-08-13
Director/Board Member 58 -
Director/Board Member 50 2020-09-30
Change 5-day change 1-year change 3-year change Capi.($)
-21.87%-.--% - - 723M
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average -0.31%+5.90%+46.59%+83.14% 473.55B
Weighted average by Cap. +2.00%+6.60%+50.88%+98.31%

Financials

2026 *2027 *
Net sales 2.34B 353M 317M 291M 264M 494M 33.49B 502M 3.47B 1.39B 17.64B 1.32B 1.3B 55.57B 2.35B 353M 317M 292M 264M 495M 33.54B 502M 3.47B 1.39B 17.66B 1.33B 1.3B 55.64B
Net income 755M 114M 102M 93.86M 84.95M 159M 10.79B 162M 1.12B 447M 5.68B 426M 417M 17.9B 811M 122M 110M 101M 91.25M 171M 11.59B 174M 1.2B 481M 6.1B 458M 448M 19.22B
Net Debt - -
Projected Income Statement - Annual - China Shineway Pharmaceutical Group Limited
Logo China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Employees
2,656
Date Price Change Volume
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - China Shineway Pharmaceutical Group Limited
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
6.367CNY
Average target price
7.294CNY
Spread / Average Target
+14.56%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - China Shineway Pharmaceutical Group Limited